Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer
Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival (OS) compared to trifluridine/tipiracil alone in a Phase III clinical trial of participants with refractory metastatic colorectal cancer (mCRC) following two chemotherapy regimens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005432/en/
Further details about the OS benefit and other results from the primary analysis of the global SUNLIGHT trial will be presented at an upcoming international scientific conference.
“Findings from the SUNLIGHT trial could potentially represent a significant advancement in the treatment of patients with metastatic colorectal cancer who have progressed after two lines of standard chemotherapy,” said Nadia Caussé-Amellal, M.D., Head of Global Development, GI Indications, Oncology and Immuno-Oncology Therapeutic Area, Servier. “Combining trifluridine/tipiracil with bevacizumab demonstrated the potential to extend survival in these patients who have limited therapeutic options.”
Fabio Benedetti, M.D., Global Chief Medical Officer for Oncology at Taiho Pharmaceutical, said: “Trifluridine/tipiracil – discovered by Taiho and developed in our partnership with Servier with the cooperation of many patients and healthcare professionals – has had a significant impact on the management of colorectal cancer for thousands of patients. The results of this study may represent another advancement in the management of this disease, and we now look forward to the further analysis of secondary endpoints.”
Nearly 1.4 million people are diagnosed with colorectal cancer (CRC) each year worldwide,1 equating to 10% of the global cancer cases.1 CRC is the second most common cause of cancer mortality, accounting for 881,000 deaths globally in 2018,2 and patients with metastatic disease have a five-year survival rate of just 11%.3 Standard chemotherapy regimens for mCRC usually include a fluoropyrimidine plus irinotecan and/or oxaliplatin, with a targeted treatment – an antivascular endothelial growth factor or antiepidermal growth factor receptor – frequently added.
“The worldwide incidence of colorectal cancer is forecasted to exceed 3 million cases annually by 2040,4 and the number of deaths is predicted to increase by 69% to approximately 1.6 million per year,5” said Professor Josep Tabernero, M.D., Ph.D., Head of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain, and Primary Investigator for the SUNLIGHT trial. “New treatment options are urgently needed as we seek to reduce the growing global burden of colorectal cancer.”
#ENDS#
About SUNLIGHT
SUNLIGHT is a multinational, open-label, active-controlled, two-arm Phase III trial to investigate the efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil alone, in patients with refractory mCRC following two chemotherapy regimens. A total of 492 patients were randomly allocated (in a 1:1 ratio) to receive trifluridine/tipiracil plus bevacizumab or trifluridine/tipiracil monotherapy. The primary objective was to demonstrate the superiority of trifluridine/tipiracil plus bevacizumab over trifluridine/tipiracil alone, in terms of OS (primary endpoint). Key secondary objectives were to compare the regimens in terms of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) and quality of life (QoL), as well as the safety and tolerability of trifluridine/tipiracil plus bevacizumab in comparison with trifluridine/tipiracil monotherapy.
For more information on SUNLIGHT, please visit: https://clinicaltrials.gov/ct2/show/NCT04737187.
About trifluridine and tipiracil
Trifluridine and tipiracil is an oral nucleoside antitumor agent discovered and developed by Taiho Pharmaceutical Co., Ltd. Trifluridine and tipiracil consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is incorporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation.
About Servier
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information: www.servier.com.
Follow us on social media: LinkedIn, Facebook, Twitter
About Taiho Oncology, Inc.
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holding Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada.
For more information, visit www.taihooncology.com.
About Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma company with a focus on oncology. Taiho Pharmaceutical also has development programs in allergy and immunology, urology and consumer healthcare products. Our corporate philosophy is simple: “We strive to improve human health and contribute to a society enriched by smiles.”
For more information about Taiho Pharmaceutical Co., Ltd., please visit: https://www.taiho.co.jp/en/.
References
1 Digestive Cancers Europe. Prevalence of Colorectal Cancer. Available at: https://digestivecancers.eu/colorectal-cancer/prevalence-of-colorectal-cancer-prevalence/?menu_id=13873. Last accessed: September 2022.
2 Tabernero J., Taieb J., Prager G., et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncol. 2021.17(16): 1977–1985.
3 World Health Organization. GLOBOCAN. Cancer Today. Estimated age-standardized mortality rates (World) in 2020, colorectum, both sexes, all ages. Available at: https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=41&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&g. Last accessed: September 2022.
4 Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273208/. Last accessed September 2022.
5 World Health Organization. International Agency for Research on Cancer. Colorectal Cancer Awareness Month 2022. Available at: https://www.iarc.who.int/featured-news/colorectal-cancer-awareness-month-2022/. Last accessed: September 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005432/en/
Contact information
Servier Media Contact:
Sonia Marques
+33 (0)1 55 72 40 21
presse@servier.com
Taiho Oncology Media Contact:
Judy Kay Moore
574-526-2369
jumoore@taihooncology.com
Taiho Pharmaceutical Media Contact:
Strategic Communications
+81 (0)3-3293-2878
th-koho@taiho.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RunPod Raises $20M in Seed Funding Co-led by Intel Capital and Dell Technologies Capital8.5.2024 16:07:00 EEST | Press release
RunPod, the launchpad that empowers developers to deploy custom full-stack AI applications, today announced it raised $20M in Seed funding, co-led by Intel Capital and Dell Technologies Capital with participation from Julien Chaummond, Nat Friedman, and Adam Lewis. In conjunction with the financing, Mark Rostick, Vice President and Senior Managing Director at Intel Capital, will join RunPod’s board of directors. RunPod is a globally distributed GPU cloud computing service for training, deploying, and scaling AI models. Using RunPod’s two core products, GPU Cloud and Serverless, developers can spin up an on-demand GPU instance in a few clicks and create autoscaling API endpoints for scaling inference on AI models in production. “The ability to create and deploy AI applications at scale will be paramount to their adoption and utilization,” said Amjad Masad, RunPod investor. “The RunPod team has clearly prioritized the developer experience to create an elegant solution that enables indivi
Tigo Energy Delivers Most Powerful Solar MLPE for High-Wattage and Bifacial Modules8.5.2024 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the newest additions to the Tigo Flex MLPE product family, the Tigo TS4-X line. Designed to serve the commercial and industrial (C&I) as well as utility solar markets, Tigo TS4-X products support the latest high-power solar modules, up to 800W. Members of the TS4-X product family feature compatibility with Pure Signal™ technology in Tigo RSS Transmitters and offer a Multi-Factor Rapid Shutdown (MFRS) option with redundant safety signaling for solar systems serving the food and pharmaceutical cold-chain sectors, or other energy-critical applications. The new devices pair with an industry-leading list of third-party solar inverters to deliver design and installation flexibility for solar installers and engineering, procurement, and construction specialists (EPCs). As Levelized Cost Of Energy (LCOE) continues to drive the large-scale solar sectors, the TS4-X product lin
Cyolo Partners with Dragos to Unveil Holistic Secure Remote Access Solution for Critical Infrastructure8.5.2024 15:30:00 EEST | Press release
Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats. New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access. This interoperability is designed to provide OT customers visibility and management of their asset inventory and e
John Patton, Head of Kindeva Drug Delivery’s Scientific Advisory Board, Named Winner of RDD Conference’s Charles G. Thiel Award8.5.2024 15:00:00 EEST | Press release
At the recent Respiratory Drug Delivery (RDD) Conference, John Patton, Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award. This prestigious award is given once every two years at RDD Conferences to one scientist who has been voted by his or her peers to have pioneered significant developments in one or more aspects of the science and technology surrounding respiratory drug delivery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508931671/en/ Biotechnology scientist and entrepreneur and Kindeva Drug Delivery’s Head of the Scientific Advisory Board, John Patton (second from the left), was named the winner of the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery at this year’s Respiratory Drug
TXOne Networks, Leader in Cyber-Physical Systems (CPS) Security, Raises $51 Million in Total in Series B Extension Round Funding8.5.2024 14:38:00 EEST | Press release
TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, today announced a significant achievement of securing $51 million in its Series B extension round of financing. In addition to TGVest Capital, the lead investor of the B round, Pegatron Group, CDIB Capital Group and CDIB-Innolux II L.P. are continuing to invest. New investors include the Taiwania Capital and Applied Ventures ITIC Innovation Fund, L.P. (AVITIC), a joint fund of Applied Ventures, LLC and ITIC-Taiwan (Industrial Technology Investment Corporation). TXOne Networks completed its Series A financing in August 2021 and announced Series B financing in August 2022. TXOne Networks works with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense of industrial control systems (ICS) and operational technology (OT) environments. With TXOne Networks, companies in diverse OT verticals implement tailored defense, including the adoption of adv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom